Stockwinners Market Radar for May 06, 2018 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:44 EDT Dentsply Sirona closes OraMetrix acquisition, to provide clear aligner solution - On May 1st, 2018, Dentsply Sirona closed the acquisition of OraMetrix, a leading provider of innovative 3-D technology solutions improving the quality and efficiency of orthodontic care. OraMetrix offers an advanced, CAD platform developed for dental professionals to deliver consistently predictable orthodontic outcomes. Dentsply Sirona says the acquisition will enable it to provide a comprehensive orthodontic offering that will include a full arch clear aligner solution. OraMetrix has revenues of approximately $20M and is profitable. In order to accelerate and broaden the commercialization of OraMetrix's technologies and services, Dentsply Sirona is planning to incur additional investments and expenses which will be slightly dilutive to overall earnings per share in 2018 and 2019.

16:31 EDT Elaine Wynn comments on ISS recommendation Wynn shareholders 'WITHHOLD' votes - Elaine Wynn, co-founder and the largest shareholder of Wynn Resorts announced that, in a report issued on May 5, 2018, Institutional Shareholder Services, one of the world's leading independent proxy advisor firms, has recommended that Wynn shareholders "WITHHOLD" votes from legacy director nominee John Hagenbuch at the company's annual meeting on Wednesday, May 16, 2018, in Las Vegas, Nevada. ISS also recommended that shareholders vote "AGAINST" approval of Wynn Resorts' say-on-pay proposal. Commenting on the ISS report, Wynn said, "I am pleased to see further support for my efforts to ensure that the company takes the actions necessary to truly become the 'New Wynn.' I urge my fellow shareholders to join me in voting for accountability ad objective oversight in the Wynn Resorts board room." ISS joins independent proxy advisor firm Glass Lewis in supporting Wynn's call to vote WITHHOLD on legacy director John Hagenbuch at this year's 2018 Annual Meeting. Wynn believes that Hagenbuch's role as a longtime member of the Compensation Committee and on the Special Committee responsible for overseeing the investigation into allegations of sexual harassment by his close friend, Stephen Wynn, the company's former Chairman and CEO are problematic and concerning. Commenting on the actions by the legacy directors in response to the allegations against Wynn, ISS said: "This election will serve as a referendum not only on whether the current board has done enough to stem the fallout of the accusations against Steve Wynn, but also on whether the current board composition is sufficiently robust to minimize the possibility that similar issues reemerge in the future. In summarizing its recommendation that shareholders should "WITHHOLD" votes from Mr. Hagenbuch, ISS commented: "[T]he dissident's campaign underscores the fact that Hagenbuch was part of a legacy board that oversaw material failures in governance and risk oversight. Given that the benefits of his continued presence on the board do not seem to outweigh the risks associated with permanence, shareholders are recommended to WITHHOLD votes for incumbent nominee Hagenbuch." Regarding the Company's executive compensation package, ISS noted that "[t]he company has a history of pay concerns," and further said: "[T]here are several problematic elements of the pay program that undermine the positive features and weaken the alignment between pay and performance."

10:35 EDT Angolan consortium signs firm purchase agreement for six Bombardier Q400 - Bombardier Commercial Aircraft announced that it has signed a firm purchase agreement for six new Q400 aircraft with African Aero Trading on behalf of the consortium forming Air Connection Express, Transportes Aereos S.A, based in Luanda, Republic of Angola. Based on the list price of the Q400 aircraft, the firm order is valued at approximately $198M. The airline will operate the Q400 domestically to connect smaller communities and increase frequencies as a regional feeder airline to TAAG Angola Airlines - flag carrier of the Republic of Angola.

10:31 EDT J&J's Janssen announces results from Phase 3 studies of esketamine nasal spray - The Janssen Pharmaceutical Companies of Johnson & Johnson announced the results from two Phase 3 clinical studies of the investigational compound esketamine nasal spray in patients with treatment-resistant depression. Data from a study in adults with treatment-resistant depression showed that flexibly dosed esketamine nasal spray plus a newly initiated oral antidepressant demonstrated a statistically significant, clinically meaningful rapid reduction of depressive symptoms as compared to placebo nasal spray plus a newly initiated oral antidepressant. The study defined treatment-resistant as patients who had not responded to two or more currently available antidepressants of adequate dose and duration in the current episode of depression. Data from a second study, in elderly patients aged 65 and older with treatment-resistant depression, which is the first study of its kind, showed treatment with flexibly dosed esketamine plus a newly initiated oral antidepressant demonstrated clinically meaningful effects compared to placebo nasal spray plus a newly initiated oral antidepressant. However, the study narrowly missed statistical significance for its primary efficacy endpoint. If approved by the U.S. Food and Drug Administration, esketamine would be one of the first new approaches to treat refractory major depressive disorder available to patients in the last 50 years. These findings represent two of the five Phase 3 studies that comprise Janssen's treatment-resistant depression program with esketamine nasal spray. The results from these studies will inform regulatory filings for esketamine nasal spray in treatment-resistant depression, for which Janssen has received Breakthrough Therapy Designations from the U.S. FDA. Data from other Phase 3 studies will be presented later in 2018.